BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-187@pharmaconomics
DTSTAMP:20260707T020343Z
DTSTART;VALUE=DATE:20270227
DTEND;VALUE=DATE:20270228
SUMMARY:CGEM PDUFA — Zipalertinib
DESCRIPTION:The FDA's approval decision on Zipalertinib for EGFR ex20ins NSCLC is due Feb 27\, 2027. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/187
URL:https://pharmaconomics.com/e/187
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CGEM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR